Novartis
Continuous Manufacturing: Novartis’ experiment in the future of drug production
June 9, 2017Manufacturing and Production, Medical Communications Novartis, continuous manufacturing
Continuous manufacturing has long been touted as the future of drug production. Pharmafile approached Novartis for more details about its successes in …
Novartis and IBM form breast cancer research partnership
June 7, 2017Research and Development Novartis, ibm
Novartis is to join forces with tech giant IBM and its Watson Health platform to tackle advanced breast cancer with …
Mounting US pricing pressures cutting into quarterly sales, Novartis admits
May 31, 2017Research and Development, Sales and Marketing Novartis, Sandoz
Novartis has revealed that increasing pressure on pricing in the US has impacted its second-quarter business, cutting into sales generated …
FDA approves Novartis’ Zykadia as first-line lung cancer treatment
May 30, 2017Manufacturing and Production, Sales and Marketing FDA, NSCLC, Novartis
The FDA has announced it has approved Novartis’ Zykadia (ceritinib) as a first line treatment in the expanded indication of …
Novartis cuts 500 traditional roles for 350 ‘high-tech’ ones
May 22, 2017Manufacturing and Production, Research and Development, Sales and Marketing Novartis
Novartis has announced a restructure within the company which will lead to the transfer or loss of 500 traditional production …
GSK mulls $8 billion healthcare consolidation deal
May 15, 2017Sales and Marketing GSK, Novartis
When GSK and Novartis first agreed their business swap and healthcare joint venture, it was seen as marking a shift …
Novartis signs drug access deal with Pakistan government
May 12, 2017Medical Communications, Sales and Marketing Islamabad, Novartis, Pakistan, market access
Pakistan’s Ministry of National Health Services, Regulations and Coordination has signed an agreement with Novartis to improve access to medicines …
Kymab instates first Chief Medical Officer
May 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, kymab
Kymab, a therapeutic antibody company based in Cambridge, UK, has announced that it has appointed Dr Sonia Quaratino as its …
Allergan and Novartis join forces to develop NASH combo therapy
April 18, 2017Manufacturing and Production, Research and Development Allergan, Novartis, nash
Allergan and Novartis have announced a new partnership to conduct a clinical trial in the treatment area of non-alcoholic steatohepatitis …
Novartis takes on dry-eye market with drug in-licensing move
April 7, 2017Medical Communications, Sales and Marketing Lubris, Novartis, dry eye
Novartis has announced that its eyecare-focused division Alcon has in-licensed dry-eye drug ECF843 from US firm Lubris for ophthalmic indications …
Novartis combo expands into lung cancer with EU approval
April 4, 2017Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist
Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …
Novartis investigational CAR-T therapy gets FDA priority review
March 30, 2017Sales and Marketing CTL019, FDA, Novartis, leukaemia
Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T) has been awarded has been awarded priority review by …
EMA recommends suspension of 331 drugs over testing concerns
March 28, 2017Manufacturing and Production, Sales and Marketing Aurobindo, Micro Therapeutic Research Labs, Novartis, Sandoz
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has called for the suspension of 331 drugs due to …
Novartis heart failure drug sinks at Phase 3 trials
March 22, 2017Research and Development Acute heart failure, Novartis, serelaxin
Novartis’ serelaxin was once thought to be the major hope for its cardiovascular pipeline – analysts projected it to become …
Novartis’ psoriasis drug allows some patients to go into remission
March 21, 2017Research and Development Cosentyx, Novartis, psoriasis
Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of …
Latest content
FibroFind appoints Lee Borthwick as CEO
